VigenCell "Primary Endpoint Achieved"... Will a Domestic NK/T Lymphoma New Drug Be Born?
VigenCell has announced plans to apply for conditional approval within the year as it successfully completed commercialization clinical trials for...
Search results for "k-bio"
"Is Waking Up at 5 AM the Key to Success?": The Uncomfortable Truth About Early Rising
At 5 AM, while darkness still lingers, a subset of the population is already turning off alarms to exercise, journal, and read.
The Electric Bond: How Mussel-Inspired Adhesives are Restoring Severed Nerves
Whether it is a victim of a car accident with severed peripheral nerves, an athlete with a torn muscle, or a patient...
The "Mini Jet Lag" of Spring: Why Your Body Struggles with Seasonal Transitions
If your body feels unusually heavy and unrefreshed despite getting enough sleep lately, the culprit may not be your...
Onconic’s ‘Nesuparib’ Secures U.S. FDA Orphan Drug Designation for Small Cell Lung Cancer
Onconic Therapeutics announced on the 24th that its novel anti-cancer candidate, 'Nesuparib', has been designated as an...
U.S. and EU Escalate Pressure on China: A Turning Point for K-Bio?
As the United States prepares to announce the initial regulatory targets of the Biosecurity Act this week, market...
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval
South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
K-Toxins Heading to China... Will Hugel Be Followed After 5 Years in the Top 3?
Domestic botulinum toxin companies are racing towards the Chinese market. With Hugel, which entered China first,...
Oral Obesity Drug Launched in the U.S.… Where is K-Bio Pharmaceutical Now?
Denmark's Novo Nordisk's obesity drug ‘Wegovy Pill (ingredient name Semaglutide)’ has recently been launched in the U. S.
SK Bioscience Launches Quadrivalent Meningococcal Vaccine 'MenQuadfi' in Korea
SK Bioscience announced on the 9th that it has launched the quadrivalent meningococcal conjugate vaccine 'MenQuadfi' in...